Product image of Microgynon 30 (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Microgynon 30

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Microgynon 30 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Microgynon 30, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 150 µg levonorgestrel tablet for oral use. It works to prevent pregnancy and can also be used to regulate menstrual cycles in women of reproductive age. The formulation combines a synthetic estrogen with a progestogen to provide reliable cycle control.

GNH India supplies Microgynon 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bayer B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Microgynon 30, a combined oral contraceptive, is indicated for hormonal regulation of the reproductive system.

  • Prevention of pregnancy: provides reliable contraceptive protection when taken as directed.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns.
  • Management of dysmenorrhea: can reduce menstrual pain associated with irregular cycles.

How It Works

  • Microgynon 30 combines ethinylestradiol, a synthetic estrogen, with levonorgestrel, a progestogen. The estrogen suppresses follicle‑stimulating hormone, while the progestogen blocks the luteinizing hormone surge, preventing ovulation. Levonorgestrel also thickens cervical mucus and induces endometrial changes that are unfavorable for implantation, together delivering contraceptive efficacy.

Side Effects

Microgynon 30 may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild stomach upset, especially when starting therapy.
  • Headache: transient tension‑type headaches.
  • Breast tenderness: mild discomfort or swelling.
  • Spotting or breakthrough bleeding: irregular bleeding during the first cycles.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention.
  • Hepatic adenoma: benign liver tumor, reported rarely.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

Before prescribing Microgynon 30, clinicians should consider several safety precautions.

  • Assess cardiovascular risk: avoid in women with history of thromboembolic disorders.
  • Screen for smoking status: contraindicated in smokers over 35 years.
  • Evaluate liver function: use with caution in hepatic impairment.
  • Consider migraine history: avoid in patients with migraine with aura.
  • Review medication list: potential interactions may reduce efficacy.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Microgynon 30 can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive efficacy.
  • Rifampicin or other strong CYP3A4 inducers: can lead to contraceptive failure.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole): may increase hormone levels, raising risk of side effects.
  • Antiretroviral protease inhibitors (e.g., ritonavir): can affect hormone metabolism, requiring monitoring.
  • St. John’s wort: herbal inducer that may lower contraceptive effectiveness.

Frequently Asked Questions

Microgynon 30 is a combined oral contraceptive indicated for preventing pregnancy and for regulating menstrual cycles in women of reproductive age. It may also be prescribed to alleviate menstrual‑related discomfort such as dysmenorrhea.

Ethinylestradiol is a synthetic estrogen that suppresses the release of follicle‑stimulating hormone from the pituitary gland, thereby inhibiting the growth of ovarian follicles. This estrogenic effect, together with the progestogenic action of levonorgestrel, prevents ovulation and contributes to contraceptive efficacy.

The dosing schedule for Microgynon 30 is determined by the prescribing clinician. Typically, the product is taken once daily for 21 consecutive days followed by a hormone‑free interval, but the exact regimen should be confirmed with a qualified health professional.

Microgynon 30 is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause fetal harm. Safety during breastfeeding has not been established; women should consult their healthcare provider before using any hormonal contraceptive while nursing.

To order Microgynon 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microgynon 30 contains 30 µg ethinylestradiol and 150 µg levonorgestrel, a dose combination that balances contraceptive efficacy with a relatively low estrogen exposure. Compared with higher‑dose formulations, it may present a reduced risk of estrogen‑related side effects while maintaining reliable pregnancy prevention.

Microgynon 30 tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and keep them out of reach of children.

Microgynon 30 is taken orally, usually with water, once each day at the same time. The tablets are swallowed whole; they should not be split, crushed, or chewed unless specifically instructed by a healthcare professional.

The most serious risks include venous thromboembolism (blood clots), hepatic adenoma (benign liver tumor), and severe allergic reactions such as anaphylaxis. Women with a history of clotting disorders, smoking over age 35, or certain migraine types should be evaluated carefully before use.

Microgynon 30 is contraindicated in women with known or suspected pregnancy, active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, breast cancer, or those who smoke heavily and are over 35 years old. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT